A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506996-89-00

Acronym

MK-3543-017

Enrollment

Registered

2024-04-15

Start date

2024-06-13

Completion date

Unknown

Last updated

2026-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myeloproliferative Neoplasms (Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis)

Brief summary

Percentage of participants with one or more adverse events (AEs), Percentage of participants who discontinued study treatment due to an AE

Detailed description

For participants with ET or PV: Duration of clinicohematologic response, For participants with ET or PV: Duration of hematologic remission, For participants with ET or PV: Transformation to MF or myelodysplastic syndrome (MDS)/ acute myeloid leukemia (AML), For participants with MF: Worsening of splenomegaly or transformation to MDS/AML, For participants with MF, ET, or PV: Thrombotic events, For participants with MF, ET, or PV: Major hemorrhagic events

Interventions

DRUGMK-3543

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percentage of participants with one or more adverse events (AEs), Percentage of participants who discontinued study treatment due to an AE	—

Secondary

Measure	Time frame
For participants with ET or PV: Duration of clinicohematologic response, For participants with ET or PV: Duration of hematologic remission, For participants with ET or PV: Transformation to MF or myelodysplastic syndrome (MDS)/ acute myeloid leukemia (AML), For participants with MF: Worsening of splenomegaly or transformation to MDS/AML, For participants with MF, ET, or PV: Thrombotic events, For participants with MF, ET, or PV: Major hemorrhagic events	—

Measure

Time frame

—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026